1. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab
- Author
-
Sekito, Takanori, Takamoto, Atsushi, Kobayashi, Yasuyuki, Mitsui, Masao, Watari, Shogo, Kubota, Risa, Sadahira, Takuya, Iwata, Takehiro, Nishimura, Shingo, Edamura, Kohei, Sako, Tomoko, Araki, Motoo, Watanabe, Masami, Watanabe, Toyohiko, Shibata, Rei, Ennishi, Daisuke, and Nasu, Yasutomo
- Subjects
Male ,renal cell carcinoma ,Middle Aged ,urologic and male genital diseases ,Ipilimumab ,Nephrectomy ,female genital diseases and pregnancy complications ,Kidney Neoplasms ,Fumarate Hydratase ,Antineoplastic Agents, Immunological ,Nivolumab ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,fumarate hydratase-deficient renal cell carcinoma ,Tomography, X-Ray Computed ,neoplasms ,Carcinoma, Renal Cell ,Germ-Line Mutation - Abstract
We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC). The International Metastatic RCC Database Consortium risk score was intermediate, and immunotherapy with nivolumab and ipilimumab (Ipi/ Nivo) was initiated. Four cycles of Ipi/Nivo and 5 cycles of nivolumab resulted in a complete response of the metastases. Hypophysitis occurred as an immune-related adverse event after four cycles of Ipi/Nivo. The prognosis of patients with FH-deficient RCC is generally poor. Few reports of FH-deficient RCC successfully treated with Ipi/Nivo have been published. Ipi/Nivo can be effective for treating FH-deficient RCC.
- Published
- 2021